newsfilter
← Earnings
Earnings Releases·

Cue Biopharma — Third Quarter 2026 Earnings Summary

  • Q3 2026 revenue declined to $0.1 million from $2.1 million in Q3 2025 due to reduced recognition under the BI Collaboration, while net loss widened to $50.0 million from $7.4 million, driven by a surge in R&D and G&A expenses largely attributed to non-cash stock-based compensation.
  • CUE-221 demonstrated highly statistically significant Phase 2 results in chronic spontaneous urticaria, showing durable benefit at week 28 and 78% complete hive resolution in high IgE subgroups, with FDA clearance obtained for a food allergy IND application.
  • The company advanced its pipeline by initiating first-in-human Phase 1 dosing for CUE-401, its first autoimmune therapeutic candidate designed as a dual-agonist to drive Treg-mediated tolerance.
  • A Second Amendment to the ImmunoScape License Agreement increased the total payment obligation to $5.5 million, with $3.0 million scheduled for Q4 2026, while the company ended the quarter with $57.9 million in cash and cash equivalents.
Company
CUE BIOPHARMA INC
Sector
Healthcare
Industry
Biotechnology